Stockscreener 앱 받기
1.16
2.52%
-0.03
전일 마감가:
$1.19
열려 있는:
$1.19
하루 거래량:
391.13K
Relative Volume:
1.69
시가총액:
$63.24M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
-4.4615
EPS:
-0.26
순현금흐름:
$28.98M
1주 성능:
-1.69%
1개월 성능:
-8.66%
6개월 성능:
-22.92%
1년 성능:
-4.13%
1일 변동 폭
$1.14
$1.23
1주일 범위
$1.12
$1.23
52주 변동 폭
$1.01
$1.89
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SPRO | 1.16 | 63.24M | 76.19M | -1.61M | 28.98M | -0.26 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Spero Therapeutics' (SPRO) "Hold" Rating Reiterated at TD Cowen - MarketBeat
TD Cowen Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Spero Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartzy
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Reports Wider Q3 Loss, Revenue Falls 47% Amid Restructuring | SPRO Stock News - StockTitan
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 - Barchart
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnin - GuruFocus.com
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings - Yahoo Finance
Spero Therapeutics (SPRO) Scheduled to Post Earnings on Thursday - Defense World
Spero Therapeutics (SPRO) to Release Earnings on Thursday - MarketBeat
Spero Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
HC Wainwright Expects Higher Earnings for Spero Therapeutics - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Spero shares hold Buy rating with target lowered on SPR720 Phase 2a results - Investing.com UK
HC Wainwright Cuts Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00 - MarketBeat
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding - Simply Wall St
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Cambridge biotech pulls plug on lung disease drug, cuts 39% of workforce - The Business Journals
Spero Therapeutics to lay off 39% of employees - PharmaLive
Spero Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com South Africa
Spero Therapeutics to Lay Off 39% of Employees - BioSpace
Spero Therapeutics stock hits 52-week low at $1.03 - Investing.com
Spero’s stock slides after antibiotic flops in Phase II trial - Yahoo Finance
Spero Therapeutics reports setback in SPR720 study By Investing.com - Investing.com South Africa
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies - Law360
Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program - MarketWatch
Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics reports setback in SPR720 study - Investing.com India
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Dodges Investor Suit Over FDA Approval (1) - Bloomberg Law
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - The Manila Times
Spero Therapeutics Announces Presentation of SPR719 (Active - GlobeNewswire
Spero Therapeutics reports promising in vitro NTM treatment data - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Market Insight: Spero Therapeutics Inc (SPRO)’s Notable Drop, Closing at 1.24 - The Dwinnex
An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily
Spero Therapeutics' (SPRO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Spero Therapeutics reports promising Phase 1 trial results for NTM-PD drug - Investing.com
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy - ForexTV.com
Spero Therapeutics Announces Publication of SPR720 Phase 1 - GlobeNewswire
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):